McKesson Corporation (MCK) Stock

Understand McKesson Corporation: how it makes money

McKesson distributes branded, generic, and specialty drugs plus medical-surgical products to U.S. pharmacies, hospitals, and specialty practices, earning a thin margin on very high sales volume. The U.S. Pharmaceutical and Oncology & Multispecialty segments together drive roughly 87% of revenue, tying the business tightly to drug distribution flow and the GLP-1 pipeline.

McKesson earns roughly 1% operating margin on over $105B in quarterly revenue, so the P&L is driven almost entirely by drug volume flowing through the channel (GLP-1 launches, biosimilar switches, oncology expansion) rather than by pricing power; the moat is the entrenched two-sided network linking major pharma makers to pharmacies and hospitals.

Business quality (Solid): A classic high-throughput, low-margin distribution model: 3.5% gross margin and 1.3% operating margin mean volume and inventory efficiency are everything. The business scores 'Solid' quality because the healthcare logistics role is essential, recurring, and deeply embedded in supply-chain relationships, but the thin margin leaves little cushion for working-capital shocks or regulatory disruption.

Valuation: At 22× earnings, MCK trades in line with the Wholesale average (24×).

Bull case

• Oncology segment 33% growth: Oncology and Multi-Specialty revenue increased 33% to $14.2 billion in the quarter, making it the fastest-growing and margin-expanding line in the portfolio. This segment is shifting the mix away from pure volume distribution toward higher-value clinical services.
• GLP-1 volume tailwind intact: Management expects continued GLP-1 growth throughout fiscal 2027. Because McKesson distributes the dominant obesity and diabetes drugs, even a modest share of the growing GLP-1 market flows through its pipeline, adding high-margin specialty volume on top of the existing base.
• Trades below industry multiple: McKesson screens at 22.2x earnings versus the 24x Wholesale industry average, a 6% discount. Given triple-digit growth in the oncology line and the GLP-1 tailwind, the stock prices in a modest undervaluation relative to structural peers.

Bear case

• IRA Part B overhang: Potential IRA Part B effects remain uncertain, and any mandated drug-pricing reform or coverage change could compress the gross margin on the $79.1B U.S. Pharmaceutical segment where nearly all revenue sits. Regulatory surprise on a 75%-of-revenue segment is a material equity risk.
• Negative free cash flow: First-quarter free cash flow remained negative despite year-over-year improvement. The distribution model requires heavy working capital to inventory drugs before selling them, and if GLP-1 volume ramps faster than collections, cash burn could persist for multiple quarters.
• Generic timing cuts ahead: Generic favorability arrived early and may pressure later quarters. When the company books more generic volume in Q1, the lower-margin mix temporarily flatters results, meaning the back half of the fiscal year carries a built-in headwind to pharmaceutical segment operating profit.

McKesson Corporation earnings call transcripts

• MCK Q3 FY26 earnings call transcript (reported 2026-02-04) · analysis
• MCK Q1 FY26 earnings call transcript (reported 2025-08-06) · analysis

All MCK earnings calls

Related Companies (Wholesale; 8 comparable wholesalers)

• Cencora, Inc. (COR)
• Cardinal Health, Inc. (CAH)
• Cigna Corporation (CI)
• Sysco Corporation (SYY)
• Medline Inc. (MDLN)
• TD SYNNEX Corporation (SNX)
• Henry Schein, Inc. (HSIC)
• Amneal Pharmaceuticals, Inc. (AMRX)